Physician profile
Eric Schenkel
NPI 1306958939
$844,554.97
in general payments reported to CMS, 2019-2025
42 companies · $74K in 2025
The $74K reported for 2025 was more than what 97% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154K · 2020: $56K · 2021: $82K · 2022: $151K · 2023: $171K · 2024: $156K · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $316K · Travel and Lodging: $65K · Food and Beverage: $15K · Consulting Fee: $5,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $316,039.64 |
| Travel and Lodging | $65,491.02 |
| Food and Beverage | $14,554.83 |
| Consulting Fee | $5,255.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $306,231.82 | 2019-2025 | Dupixent |
| Genzyme Corporation | $203,746.51 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $137,911.97 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $73,287.31 | 2019-2025 | Nucala |
| Optinose US, INC. | $62,818.26 | 2019-2025 | |
| Alk-Abello, INC | $18,394.11 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Takeda Pharmaceuticals U.S.A., INC. | $14,280.14 | 2020-2025 | Takhzyro, Cuvitru, Eohilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $7,637.38 | 2019-2023 | Spiriva Respimat |
| Merck Sharp & Dohme LLC | $6,255.79 | 2019-2022 | |
| Pharming Healthcare, INC. | $4,281.49 | 2019-2023 | Ruconest |
| Novartis Pharmaceuticals Corporation | $2,775.45 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,839.16 | 2019-2021 | |
| Csl Behring | $957.42 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Biocryst US Sales Co., LLC | $593.39 | 2021-2025 | Orladeyo |
| Pfizer INC. | $449.82 | 2019-2024 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Schenkel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.